IHH Healthcare has a total of 19 patents globally, out of which 3 have been granted. Of these 19 patents, more than 52% patents are active. Turkey is where IHH Healthcare has filed the maximum number of patents, followed by United States of America and Europe. Parallelly, Turkey seems to be the main focused R&D centre and Malaysia is the origin country of IHH Healthcare.
IHH Healthcare was founded in the year 1974. The Company provides healthcare services. The Company operates hospitals as well as medical centres, clinics and ancillary healthcare businesses across multiple countries. As of March 2023, the market cap of IHH Healthcare is $11.84 Billion.
Do read about some of the most popular patents of IHH Healthcare which have been covered by us in this article and also you can find IHH Healthcare patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over IHH Healthcare patent portfolio.
How many patents does the CEO of IHH Healthcare have?
The CEO Kelvin Loh has 0 patent.
How many patents does IHH Healthcare have?
IHH Healthcare has a total of 19 patents globally. These patents belong to 11 unique patent families. Out of 19 patents, 10 patents are active.
How Many Patents did IHH Healthcare File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
|Year of Patents Filing or Grant||IHH Healthcare Applications Filed||IHH Healthcare Patents Granted|
How many IHH Healthcare patents are Alive/Dead?
How Many Patents did IHH Healthcare File in Different Countries?
Countries in which IHH Healthcare Filed Patents
|United States Of America||2|
|Hong Kong (S.A.R.)||1|
Where are Research Centres of IHH Healthcare Patents Located?
List of IHH Healthcare Patents
|IHH Healthcare Patents||Title|
|US20060263785A1||Detection Of Aneuploidy|
|WO2022050915A1||Method For Production Of Fast, Inclusive And High-Dose Inactive Adjuvant Positive Vaccine To Be Used Against Sars-Cov-2 Virus|
|WO2022039687A1||Method For Production Of Fast, Inclusive And High-Dose Inactive Vaccine To Be Used Against Sars-Cov-2 Virus|
|WO2021101466A1||A Method For Producing Multiverse Specific T Cells|
|TR202110552A2||Development Of A Chimeric Antigen Receptor (Car) Expressing Car-U937 Monocyte Cell Line And Its Use In Cancer Immunotherapy|
|TR201917367A1||A Method For Manufacturing A Product Suitable For Use In Hair Loss And Scar Treatment|
|TR202018115A2||Laboratory And Clinical Test Method For Monitoring T Cell Response In Diagnosis And Follow-Up Of Covid 19 Disease|
|TR202014033A2||A Fast, Inclusive And High-Dose Inactive Adjuvant Positive Vaccine Manufacturing Method For Use Against Sars-Cov-2 Virus|
|TR202018990A2||Methods For The Production Of Gene Products Suitable For Use In The Treatment Of Haemophilia A|
|TR202013279A2||A Fast, Inclusive And High-Dose Inactive Vaccine Manufacturing Method To Use Against Sars-Cov-2 Virus|
|TR201918028A2||A Method For Redesign And Expansion Of Nk92 Cells For Use In Immunotherapy|
|TR201918044A2||A Method For The Production Of Multiverse Specific T Cells|
|SG119192B||Detection Of Aneuploidy|
|AU2004202841A1||Detection Of Aneuploidy|
|MYPI2004002501A0||Detection Of Aneuploidy|